BeiGene, Ltd. Earnings

The next earnings date for BeiGene, Ltd. has not yet been scheduled.

Analyst Estimates of BeiGene, Ltd. Earnings

No Results.

Report Date	Estimated Earnings Per Share
No Results.

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

BeiGene, Ltd. Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
05/07/2025	---	$0.02	102.46%
02/27/2025	---	$-1.43	-40.54%
11/12/2024	---	$-1.15	-3.24%
08/07/2024	---	$-1.15	46.33%
05/08/2024	---	$-2.41	5.30%
02/26/2024	---	$-3.48	-0.76%
11/10/2023	---	$2.01	---
08/02/2023	---	$-3.64	---
05/04/2023	---	$-3.34	---
02/27/2023	---	$-4.29	---
11/09/2022	---	$-5.39	---
08/04/2022	---	$-5.56	---
05/05/2022	---	$-4.24	---
02/25/2022	---	$-6.16	---
11/05/2021	---	$-4.46	---
08/06/2021	---	$-5.23	---
05/07/2021	---	$0.69	---
02/26/2021	---	$-5.16	---
11/06/2020	---	$-4.81	---
08/07/2020	---	$-4.31	---
05/11/2020	---	$-4.70	---
03/02/2020	---	$-6.30	---
11/13/2019	---	$-5.11	---
08/09/2019	---	$-1.43	---
05/10/2019	---	$-2.81	---
02/27/2019	---	$-4.49	---
11/07/2018	---	$-2.41	---
08/30/2018	---	$-2.63	---
05/10/2018	---	$-1.75	---
03/01/2018	---	$-1.66	---
11/14/2017	---	$1.97	---
08/10/2017	---	$-1.01	---
05/11/2017	---	$-0.85	---
03/23/2017	---	$-0.63	---
11/10/2016	---	$-0.59	---
08/11/2016	---	$-0.40	---
05/12/2016	---	$-0.37	---

More About BeiGene, Ltd.

Website

https://beonemedicines.com

Country

USA

Full Time Employees

11,000

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines Ltd. in May 2025. BeOne Medicines Ltd. was incorporated in 2010 and is based in Basel, Switzerland.

“BeiGene, Ltd. Earnings” Can Refer to the BeiGene, Ltd. Earnings Date

Some people say “BeiGene, Ltd. earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my BeiGene, Ltd. position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning BeiGene, Ltd. Stock on the Earnings Date

If you own BeiGene, Ltd. stock (ONC) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for BeiGene, Ltd. might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading BeiGene, Ltd. shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More BeiGene, Ltd. Earnings

You can contact us any time if you would like to ask questions about BeiGene, Ltd. earnings or anything else related to the stock market.